EUVIMEDEUVIMED entdecken
Open Access

Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes After Reintroduction of Chemotherapy

Natanja Oosterom iD, Saskia L M Gooskens, Lindsay A Renfro, Elizabeth J Perlman iD, Marry M van den Heuvel-Eibrink, Thomas E Hamilton, Daniel M Green iD, Paul E Grundy iD, Najat C Daw iD, James I Geller, Jeffrey S Dome iD, Conrad V Fernandez iD und 1 weitere

Journal of Clinical Oncology · 2023

DOI: 10.1200/jco.22.02555 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Natanja Oosterom und 12 weiteren Autor:innen. Beteiligte Einrichtung: Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Wilms Tumor, Kidney Neoplasms, Thrombocytopenia, Liver Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The safety of reintroducing chemotherapy in the pediatric renal tumor setting after severe hepatopathy (SH), including sinusoidal obstruction syndrome (SOS), is uncertain. We describe the incidence, severity, outcomes, and impact on subsequent treatment for patients with SH from National Wilms Tumor Study (NWTS) protocols 3-5. PATIENTS AND METHODS Archived charts for patients enrolled on NWTS 3-5 who met study inclusion criteria for SH by using established hepatopathy grading scales and clinical criteria were reviewed for demographics, tumor characteristics, radio- and chemotherapy details, SH-related dose modifications, and oncologic outcomes. Genomic analysis for candidate polymorphisms associated with SH was performed in 14 patients. RESULTS Seventy-one of 8,862 patients (0.8%) met study inclusion criteria. The median time from therapy initiation to SH was 51 days (range, 2-293 days). Sixty percent received radiotherapy, and 56% had right-sided tumors. Grade 1-4 thrombocytopenia was noted in 70% at initial occurrence of SH (median 22,000/microliter). Among 69 of 71 children with SH occurring before the end of therapy (EOT) and post-SH treatment information available, chemotherapy was delayed posthepatopathy for 65% (69% of these at a reduced dose), continued without delay for 20% (57% of these at reduced dose), and stopped completely for 15% (4 of 10 of whom died of SH). Overall, 42% of patients with dose reductions achieved full dose by EOT. The five-year post-SH event-free survival for patients who continued therapy was 89% (95% CI, 81 to 98), with no significant differences by whether delay or dose reduction occurred. We identified no SH-associated pharmacogenomic polymorphism. CONCLUSION The incidence of SH on NWTS 3-5 was low; many had associated severe thrombocytopenia. Careful reintroduction of chemotherapy appeared to be feasible for the majority of patients who developed severe chemotherapy- and/or radiotherapy-induced liver toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Wilms TumorKidney NeoplasmsThrombocytopeniaLiver DiseasesChildHumansInfantPrevalenceCombined Modality TherapyAntineoplastic Combined Chemotherapy Protocols

Autor:innen und Institutionen

  • Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • University of Southern California and Children's Oncology Group, Los Angeles, CA.
  • Department of Pathology and Laboratory Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.
  • Division of General, Thoracic and Fetal Surgery, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Department of Epidemiology and Cancer Control Oncology, St Jude Children's Research Hospital, Memphis, TN.
  • Department of Pediatric Oncology, University of Alberta Hospital, Edmonton, AB, Canada.

ORCID-Profile: Natanja Oosterom, Elizabeth J Perlman, Daniel M Green, Paul E Grundy, Najat C Daw, Jeffrey S Dome, Conrad V Fernandez, Elizabeth A Mullen

Förderung

  • NCI NIH HHS

Zitieren

APA

Oosterom, N., Gooskens, S. L. M., Renfro, L. A., Perlman, E. J., van den Heuvel-Eibrink, M. M., Hamilton, T. E., Green, D. M., Grundy, P. E., Daw, N. C., Geller, J. I., Dome, J. S., Fernandez, C. V., & Mullen, E. A. (2023). Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes After Reintroduction of Chemotherapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.02555

Vancouver

Oosterom N, Gooskens SLM, Renfro LA, Perlman EJ, van den Heuvel-Eibrink MM, Hamilton TE, et al. Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes After Reintroduction of Chemotherapy. Journal of Clinical Oncology. 2023. doi:10.1200/jco.22.02555

BibTeX
@article{Oosterom2023,
  author = {Oosterom, Natanja and Gooskens, Saskia L M and Renfro, Lindsay A and Perlman, Elizabeth J and van den Heuvel-Eibrink, Marry M and Hamilton, Thomas E and Green, Daniel M and Grundy, Paul E and Daw, Najat C and Geller, James I and Dome, Jeffrey S and Fernandez, Conrad V and Mullen, Elizabeth A},
  title = {Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes After Reintroduction of Chemotherapy},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  doi = {10.1200/jco.22.02555}
}
Kostenlos starten →